glp-1 agonists reduce inflammation Frontiers A clinician's perspective 📝 GLP-1

70,71 Additionally, the exploration of GLP-1R positive allosteric modulators (PAMs) offers a new regulatory approach that could enhance the therapeutic profile of small-molecule GLP-1R agonists

You might hear them called GLP-1 analogs or incretin mimetics. While the first version was approved in 2005, modern options like Ozempic, Wegovy, and Zepbound have revolutionized the field by offering once-weekly dose to get superior results

However, significant risks and uncertainties accompany off-label low-dose use

In 2019, the FDA approves semaglutide (Rybelsus), the first oral GLP-1 analog treatment for adults with type 2 diabetes

NASH can progress to cirrhosis, which is characterized by the formation of fibrous bands and regenerative nodules throughout the liver

The anti-inflammatory mechanisms appear to be independent of weight loss or glycemic improvement, suggesting direct immunomodulatory properties